Chronic Liver Disease Clinical Trial
Official title:
Responsiveness of RDR Test to Assess Hepatic Vitamin A Stores in Chronic Liver Disease
The relative-dose-response test (RDR) is considered to be the most accurate method for
evaluating vitamin A nutritional status (VANS) in patients suffering from liver disease, as
it infers the reserves of the vitamin in the liver. However, for the RDR test to reflect
VANS in patients suffering from chronic liver disease, factors inherent to the disease need
to be considered, such as possible malabsorption, advanced age, a drop in synthesis and/or
the release of retinol binding protein (RBP), which would result in an inadequate response
to the RDR test. Thus, the objective of present study is to assess the adequacy of two
different protocol for using the RDR test in patients with cirrhosis and cirrhosis-related
hepatocellular carcinoma.
Methods: The sample group was comprised of 178 patients at Federal University of Rio de
Janeiro University Hospital (111 men) with several etiologies of liver cirrhosis at
different stages in the progression of the disease. They were sorted into two groups,
according to the retinyl palmitate dosage (1500 IU or 2500 IU) received at T0 (blood sample
taken following a 12-hour fast). Following supplementation, the investigators took further
blood samples five and seven hours later (T5 and T7). The investigators assessed VANS via
concentrations of serum retinol and RBP, as well as by way of the RDR test. The cutoff
points the investigators used for denoting inadequacy in the indicators retinol and RDR
were, respectively, < 1.05 µmol/L and ≥ 20%. To classify the degrees of severity of the
disease the investigators used the criteria established by Child & Pugh (1973).
Status | Completed |
Enrollment | 178 |
Est. completion date | December 2008 |
Est. primary completion date | December 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - diagnosis of liver cirrhosis of viral etiology, alcoholic or metabolic action Exclusion Criteria: - malabsorption syndromes - moderate or severe infection - diabetes mellitus using insulin renal, cardiac or respiratory - therapeutic doses of vitamin A in the 6 months prior to data collection |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
Brazil | Gabriela Villaça Chaves | Rio de Janeiro | RJ |
Lead Sponsor | Collaborator |
---|---|
Universidade Federal do Rio de Janeiro |
Brazil,
Peres WA, Chaves GV, Gonçalves JC, Ramalho A, Coelho HS. Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease. Br J Nutr. 2011 Dec;106(11):1724-31. doi: 10.1017/S0007114511002145. Epub 2011 Jun 8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline in retinol status (RDR test) at 5 and/or 7 hour after supplementation | Therapeutic response is evaluated by means of circulating serum retinol, 5 and 7 hours after the administration of vitamin A. The RDR was calculated by the following formula, using the values of serum retinol in the three times of blood collection (Loerch et al., 1979), expressed in percentages: RDR (%) = [(A0-Ax) / Ax] x100 where A0 is the serum retinol at time 0 (fasting) and Ax is the serum retinol 5 or 7 h after administration of vitamin A. It was used as the RDR cutoff = 20%, indicating indirect hepatic reserve inadequate |
RDR will be calculated for the two intervention groups (1500 or 2500 IU vitamin A), for the two moments of blood sampling, 5 and 7 hours after supplementation. | No |
Secondary | serum retinol-binding protein (RBP) | RBP were analyzed at baseline, 5 and 7 hours after supplementation as a variable that explain the appropriate response or failure to respond to the RDR test. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03704792 -
Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference
|
N/A | |
Terminated |
NCT02949375 -
Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease
|
Phase 2 | |
Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
Completed |
NCT00756171 -
Colesevelam Versus Placebo in Cholestatic Pruritus
|
Phase 2/Phase 3 | |
Completed |
NCT01195181 -
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
|
Phase 4 | |
Completed |
NCT05044663 -
Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.
|
||
Recruiting |
NCT04588077 -
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
|
Phase 4 | |
Recruiting |
NCT04802954 -
Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients
|
N/A | |
Recruiting |
NCT04622449 -
Etiopathogenesis of Anemia in Chronic Liver Disease
|
||
Enrolling by invitation |
NCT05836246 -
The Development of Quantitative Ultrasound Imaging Software Platform
|
||
Completed |
NCT03087344 -
Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis
|
N/A | |
Completed |
NCT04751045 -
Comparison and Outcomes of Endoscopic Ultrasound Liver Biopsies Versus Percutaneous Liver Biopsies
|
N/A | |
Not yet recruiting |
NCT04526548 -
A Diagnostic Study on Patients With Drug-induced Liver Injury
|
||
Withdrawn |
NCT02899325 -
FDGal PET/CT to Detect Hepatocellular Carcinoma
|
||
Terminated |
NCT02530567 -
Non-invasive Evaluation of Portal Pressure by MRI
|
N/A | |
Suspended |
NCT02650011 -
Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease
|
||
Completed |
NCT01851252 -
MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy
|
Phase 1 | |
Terminated |
NCT01756690 -
Predicting Lung Injury From Transfusion in Patients With Liver Disease
|
N/A | |
Completed |
NCT01600105 -
Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
|
Phase 4 | |
Completed |
NCT01008293 -
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
|
Phase 2/Phase 3 |